Strengthening the Management of Clinical Trial Supplies
This white paper discusses the benefits of predictive technology to forecast the clinical supply needs of a clinical trial.
RELATED ARTICLES
New from BioClinca, a white paper on Strengthening the Management of Clinical Trial Supplies.
This white paper discusses the benefits of predictive technology to forecast the clinical supply needs of a clinical trial. It explores how sponsors can also gain insight and efficiencies by incorporating clinical supply management teams early in the process for more effective trial design, more realistic assessment of funding needs, and more productive processes throughout the life of the trial.
You can view and download the white paper here.
Below, you can also find a series of podcasts that Editor-in-Chief, Lisa Henderson, had in conversation with Victoria Dunay, Manager of the Clinical Supply Chain, Chain Optimization at BioClinica, and Nicole Garmon, Product Manager at BioClinica.
In them they discuss the trends in Clinical Trials Supply Management. Check out the podcasts below.
Getting IRT Right – Part 2: Study Drug Allocation and Supply Management
September 15th 2023In an earlier article, we reviewed the randomization risks that could arise if an interactive response technology (IRT) system isn’t designed and/or implemented correctly. Here we address the consequences that trial sponsors could face if their IRT system isn’t adequately designed to handle the many and often complex drug allocation and trial supply aspects of their clinical trials.
Master Protocols: Implementing Effective Treatment Adaptations in the Randomization
August 23rd 2023It is unrealistic to include infinite adaptations in an IRT system, thus identifying the optimal level of adaptations requires examination of the study’s characteristics and planning phase considerations.
Getting IRT Right – Part 1: Randomization
August 2nd 2023This is the first of two articles on the consequences that could arise if an interactive response technology (IRT) system isn’t designed and/or implemented correctly and how a trial could quickly go off track based on risks related to randomization, drug allocation, and trial supply.
